MOG and myeloid sarcoma: One such single-exon construct, RTL1000, containing the human MOG-35-55 peptide linked to the DR2β1 and DRα1 domains through a flexible linker was recently tested successfully in a phase 1 clinical trial in HLA-DR2+ MS subjects [44].